Purple Biotech welcomes Suzana Nahum-Zilberberg to its Board as Independent Director

– ISRAEL, Rehovot –  Purple Biotech Ltd. (TASE: PPBT | NASDAQ: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of seasoned biopharmaceutical Industry executive, Suzana Nahum-Zilberberg to its Board of Directors, bringing the Board eight members, six of whom independent.

“We are excited to welcome Suzana to our Board of Directors,” said Board Chairman, Dr. Eric Rowinsky. “Ms. Nahum-Zilberberg has extensive experience in senior leadership positions at several leading biopharmaceutical companies. As we continue to expeditiously advance CM24 and NT219, our promising anti-cancer clinical product candidates, we look forward to leveraging Suzana’s operational expertise in order to further advance our missions of developing impactful therapeutics for cancer patients and generating sustainable shareholder value.”

About Suzana Nahum-Zilberberg

Ms. Nahum-Zilberberg currently serves as Vice Chairman of the Board of BioLight Life Science, which is traded on the Tel Aviv Stock Exchange, and from 2011 to 2020 served as the CEO of BioLight. Ms. Nahum-Zilberberg also serves as a director at Human Xtention Ltd. and Nextferm Technologies Ltd., both of which are traded on the Tel Aviv Stock Exchange, and several private companies. Before joining BioLight, Ms. Nahum-Zilberberg held several leadership positions at Teva Pharmaceuticals Industries, including Vice President of Asia and Pacific and Director in the office of the President and CEO.

“I am delighted to join the Board of Directors of a company as innovative as Purple Biotech,” said Ms. Nahum-Zilberberg. “I welcome the opportunity to work with the other members of the Board and the Company’s experienced management team to continue the development of Purple Biotech’s promising clinical pipeline and support its growth for the overall business.”

Ms. Nahum-Zilberberg holds a B.A. degree in accounting and economics and an M.B.A. degree from Tel Aviv University, a Certified Director degree from Tel Aviv University, and studied at the INSEAD Asian International Executive Program. She is a certified public accountant.

About Purple Biotech

Purple Biotech Ltd. is a clinical-stage company developing first-in-class therapies by overcoming tumor immune evasion and drug resistance. The Company’s oncology pipeline includes NT219 and CM24. NT219 is a dual inhibitor, a novel small molecule that simultaneously targets IRS1/2 and STAT3. The Company is currently advancing NT219 as monotherapy treatment of solid tumors, followed by a dose escalation of NT219 in combination with cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma in a phase 1/2 study, and an expansion phase of NT219 at its recommended phase 2 level in combination with cetuximab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. CM24 is a humanized monoclonal antibody that blocks CEACAM1, an immune checkpoint protein that supports tumor immune evasion and survival through multiple pathways. The Company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in selected cancer indications in a phase 1b study followed by a phase 2 for the treatment of non-small cell lung cancer and pancreatic cancer. The Company has entered into a clinical collaboration agreement, as amended, with Bristol Myers Squibb for the planned phase 1/2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in patients with non-small cell lung cancer and in combination with nivolumab in addition to nab-paclitaxel in patients with pancreatic cancer. The Company is also the owner of Consensi, an FDA-approved fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension that was approved by the FDA for marketing in the U.S. Consensi is being sold in the U.S. by Burke Therapeutics, the marketing partner of the Company’s U.S. distributor, Coeptis Pharmaceuticals. The Company has also partnered to commercialize Consensi in China and South Korea. The Company’s corporate headquarters are located in Rehovot, Israel.

For more information: https://purple-biotech.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team